Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

ENTA’s new non-virology program is in immunology:

Thanks Dew. Looks like the tax loss selling of ENTA might be finally over as the price has risen over $11, something we haven't seen since September. Higher than normal today based on the announcement the new oral KIT inhibitor drug. I don't if I end up missing my chance to garner some losses for tax purposes. So it looks like betting on a company with great chemists and leadership along with being stubborn just might end up paying off.

Now we just need to read that PFE decided to settle in the patent lawsuit over Paxlovid and grants ENTA a milestone payments and a percentage of future earnings. If that happens, then Ralph Kramden will be describing ENTA's trajectory.